��������

Klaus Falk is a seasoned executive with extensive experience in the pharmaceutical and financial sectors. Currently serving as Senior Vice President for the Medical Unit in Germany and Deputy Managing Director at Fresenius Kabi since January 2022, Klaus has held significant leadership roles at prominent companies including Vice President at Samsung Bioepis and Head of Business Unit Biosimilars at Boehringer Ingelheim. Over a career that spans multiple decades, Klaus has also held various senior roles at Merck KGaA, Deutsche Bank, and Grünenthal. Education includes advanced management training from prestigious institutions such as Northwestern University's Kellogg School of Management, Duke University's Fuqua School of Business, and an Executive Coaching degree from Trigon Academy.